The researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users (hazard ratio, 1.07; 95% CI, 0.98 to 1.18).

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

The analysis included 14,665 pairs in the GLP-1s vs. SGLT2 inhibitors group and 13,711 pairs in the GLP-1s vs. DPP-4 inhibitors group. The researchers reported a rate difference of depression ...

New GLP-1 receptor agonist users did not have an excess risk for suicidality compared ... and death from suicide -- compared with DPP-4 inhibitor users (HR 1.02, 95% CI 0.85-1.23) or SGLT2 ...

The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected ...

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023.

During mean follow-up of 3.9 years, investigators identified 2,501 new obesity-related cancers in the GLP-1 group and 2,671 in the DPP-4 group.

GLP-1 RA exposure (exenatide, dulaglutide, liraglutide, semaglutide) was assessed over 30-day risk and reference periods, separated by a 60-day washout. Cases included adults hospitalized for ...

The rate difference was −5.78 per 1,000 person-years for GLP-1 RA users versus DPP-4i users (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.98).

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023.

The rate difference was −5.78 per 1,000 person-years for GLP-1 RA users versus DPP-4i users (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.98).